Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
Acadia Pharmaceuticals (Nasdaq: ACAD) has announced its participation in two major investor conferences in December 2024. The company will present at Citi's 2024 Global Healthcare Conference in Miami on December 3 at 10:15 a.m. ET, and the 7th Annual Evercore HealthCONx Conference in Coral Gables on December 4 at 2:35 p.m. ET. Both fireside chats will be available via webcast on Acadia.com.
Acadia specializes in neuroscience breakthroughs and has developed FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. Their current clinical-stage research focuses on Prader-Willi syndrome, Alzheimer's disease psychosis, and other neuropsychiatric symptoms in CNS disorders.
Acadia Pharmaceuticals (Nasdaq: ACAD) ha annunciato la sua partecipazione a due importanti conferenze per investitori a dicembre 2024. L'azienda presenterà alla Conferenza Globale sulla Sanità 2024 di Citi a Miami il 3 dicembre alle 10:15 ET e alla 7ª Conferenza Annuale Evercore HealthCONx a Coral Gables il 4 dicembre alle 14:35 ET. Entrambi i dibattiti informali saranno disponibili in webcast su Acadia.com.
Acadia si specializza in scoperte nel campo delle neuroscienze e ha sviluppato trattamenti approvati dalla FDA per la psicosi di Parkinson e la sindrome di Rett. La loro attuale ricerca in fase clinica si concentra sulla sindrome di Prader-Willi, sulla psicosi dell'Alzheimer e su altri sintomi neuropsichiatrici nei disturbi del SNC.
Acadia Pharmaceuticals (Nasdaq: ACAD) ha anunciado su participación en dos importantes conferencias para inversores en diciembre de 2024. La compañía presentará en la Conferencia Global de Atención Médica 2024 de Citi en Miami el 3 de diciembre a las 10:15 a.m. ET, y en la 7ª Conferencia Anual Evercore HealthCONx en Coral Gables el 4 de diciembre a las 2:35 p.m. ET. Ambas charlas se transmitirán por webcast en Acadia.com.
Acadia se especializa en avances en neurociencias y ha desarrollado tratamientos aprobados por la FDA para la psicosis en la enfermedad de Parkinson y el síndrome de Rett. Su investigación actual en fase clínica se centra en el síndrome de Prader-Willi, la psicosis del Alzheimer y otros síntomas neuropsiquiátricos en trastornos del SNC.
아카디아 제약 (Nasdaq: ACAD)는 2024년 12월에 열리는 두 개의 주요 투자자 회의에 참여한다고 발표했습니다. 이 회사는 시티의 2024 글로벌 헬스케어 회의에서 12월 3일 오전 10시 15분 ET에 마이애미에서 발표하며, 제7회 연례 에버코어 헬스CONx 회의에서 12월 4일 오후 2시 35분 ET에 코랄 게이블스에서 발표합니다. 두 개의 화상 대화는 Acadia.com을 통해 웹캐스트로 시청할 수 있습니다.
아카디아는 신경 과학 혁신에 전문화되어 있으며 파킨슨병 정신병과 레트 증후군에 대한 FDA 승인 치료제를 개발했습니다. 현재 임상 단계 연구는 프라더-윌리 증후군, 알츠하이머병 정신병 및 CNS 장애의 기타 신경정신적 증상에 중점을 두고 있습니다.
Acadia Pharmaceuticals (Nasdaq: ACAD) a annoncé sa participation à deux grandes conférences pour investisseurs en décembre 2024. L'entreprise présentera à la Conférence mondiale sur la santé 2024 de Citi à Miami le 3 décembre à 10h15 ET, et à la 7e Conférence annuelle Evercore HealthCONx à Coral Gables le 4 décembre à 14h35 ET. Les deux échanges seront disponibles en webdiffusion sur Acadia.com.
Acadia se spécialise dans les avancées en neurosciences et a développé des traitements approuvés par la FDA pour la psychose liée à la maladie de Parkinson et le syndrome de Rett. Leur recherche clinique actuelle se concentre sur le syndrome de Prader-Willi, la psychose de la maladie d'Alzheimer et d'autres symptômes neuropsychiatriques dans les troubles du SNC.
Acadia Pharmaceuticals (Nasdaq: ACAD) hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im Dezember 2024 bekannt gegeben. Das Unternehmen wird am 3. Dezember um 10:15 Uhr ET auf der Citi's 2024 Global Healthcare Conference in Miami präsentieren und am 4. Dezember um 14:35 Uhr ET auf der 7. Jahrestagung der Evercore HealthCONx in Coral Gables. Beide Gespräche werden über einen Webcast auf Acadia.com verfügbar sein.
Acadia konzentriert sich auf Neurowissenschaften und hat von der FDA zugelassene Behandlungen für die Psychose bei Parkinson und das Rett-Syndrom entwickelt. Ihre aktuelle klinische Forschung konzentriert sich auf das Prader-Willi-Syndrom, die Psychose bei Alzheimer und andere neuropsychiatrische Symptome bei Erkrankungen des zentralen Nervensystems.
- None.
- None.
Citi's 2024 Global Healthcare Conference
Fireside Chat: Tuesday, December 3, 2024 at 10:15 a.m. Eastern Time in
7th Annual Evercore HealthCONx Conference
Fireside Chat: Wednesday, December 4, 2024 at 2:35 p.m. Eastern Time in
Live webcasts of each fireside chat will be accessible on the company’s website, Acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following each presentation.
About Acadia Pharmaceuticals
Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only approved drug in
View source version on businesswire.com: https://www.businesswire.com/news/home/20241121840902/en/
Investor Contact:
Acadia Pharmaceuticals Inc.
Al Kildani
(858) 261-2872
ir@acadia-pharm.com
Source: Acadia Pharmaceuticals Inc.
FAQ
When is Acadia Pharmaceuticals (ACAD) presenting at Citi's 2024 Global Healthcare Conference?
What diseases does Acadia Pharmaceuticals (ACAD) currently focus on treating?
How can investors access Acadia Pharmaceuticals' (ACAD) December 2024 conference presentations?
What are Acadia Pharmaceuticals' (ACAD) FDA-approved treatments as of 2024?
